Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Antihistamine
Terfenadine is a prodrug that requires oxidation by CYP3A4 to its active metabolite. Inhibition of its metabolism results in elevated plasma levels of the parent compound.
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Life-threatening QT prolongation.
Aprepitant is contraindicated in patients receiving terfenadine.
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team